ASCO 2022: ASTRUM-005 Trial Demonstrates Benefits of Adding Serplulimab to Chemotherapy in First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
This was the first time overall survival was demonstrated for PD-L1 inhibition in a global phase III study
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.